SCHEMBL24257499

SCHEMBL24257499

Cc1c(-c2cnn(-c3ccccc3)c2)cnc(C(=O)O)c1OCc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 11/20 0.50
RIPK2 O43353 1/20 0.44
ALKBH1 Q13686 3/20 0.42
CCNC P24863 1/20 0.41
CDK8 P49336 1/20 0.41
KCNH2 Q12809 2/20 0.41
HPGDS O60760 1/20 0.40
ALKBH2 Q6NS38 1/20 0.40
KDM4E B2RXH2 1/20 0.40
NPC1 O15118 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
MAPK1 P28482 1/20 0.40
RAB9A P51151 1/20 0.40
GRM2 Q14416 1/20 0.40
HTR2B P41595 1/20 0.40
MTNR1A P48039 1/20 0.40
POLQ O75417 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Nitrous Acid SCHEMBL29248888 0.97 GRM4 (0.48) GRM4RIPK2ALKBH1CCNCCDK8
SCHEMBL24257566 0.93 GRM4 (0.44) GRM4RIPK2ALKBH1CCNCCDK8
SCHEMBL29248887 0.90 GRM4 (0.46) GRM4RIPK2CCNCCDK8KCNH2
SCHEMBL24257533 0.88 EGLN1 (0.46) GRM4RIPK2ALKBH1ALKBH2MAPT
Nitrous Acid SCHEMBL29248972 0.85 EGLN1 (0.44) GRM4RIPK2ALKBH1ALKBH2MAPT
SCHEMBL24257745 0.84 GRM4 (0.42) GRM4RIPK2CCNCCDK8NPC1
SCHEMBL24257808 0.84 PDK2 (0.39) ALKBH1MAPT
SCHEMBL24257760 0.82 JAK2 (0.41) ALKBH1MAPK1
SCHEMBL24257678 0.81 GRM4 (0.50) GRM4RIPK2KCNH2KDM4EALDH1A1
SCHEMBL29248959 0.81 GRM4 (0.54) GRM4CCNCCDK8KCNH2HPGDS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
CN-116670131-A PHD inhibitor compounds, compositions, and methods of use 阿克比治疗有限公司 2023-08-29 CN disclosed
EP-4196466-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE Akebia Therapeutics Inc. (US) 2023-06-21 EP disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 GRM4 3161/4885RIPK2 113/4885ALKBH1 4707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.